USANA Health Sciences (NYSE:USNA) Updates FY 2025 Earnings Guidance

USANA Health Sciences (NYSE:USNA - Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.350-3.000 for the period, compared to the consensus EPS estimate of 2.590. The company issued revenue guidance of $920.0 million-$1.0 billion, compared to the consensus revenue estimate of $941.6 million.

USANA Health Sciences Stock Up 1.3 %

Shares of NYSE:USNA traded up $0.30 during trading on Tuesday, reaching $24.13. 224,570 shares of the company's stock traded hands, compared to its average volume of 119,345. The firm has a market cap of $456.20 million, a PE ratio of 8.53, a P/E/G ratio of 0.93 and a beta of 1.00. USANA Health Sciences has a fifty-two week low of $23.10 and a fifty-two week high of $49.78. The company has a 50-day simple moving average of $28.31 and a 200-day simple moving average of $33.45.

USANA Health Sciences (NYSE:USNA - Get Free Report) last announced its earnings results on Tuesday, April 22nd. The company reported $0.73 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.74 by ($0.01). USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same quarter last year, the business posted $0.86 earnings per share. On average, equities research analysts forecast that USANA Health Sciences will post 2.45 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have issued reports on the company. DA Davidson dropped their target price on USANA Health Sciences from $38.00 to $36.00 and set a "neutral" rating for the company in a report on Thursday, February 27th. StockNews.com cut USANA Health Sciences from a "strong-buy" rating to a "buy" rating in a report on Friday, February 14th. Finally, Sidoti cut USANA Health Sciences from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, February 18th.

Insider Buying and Selling at USANA Health Sciences

In related news, insider Joshua Foukas sold 5,732 shares of the company's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $32.54, for a total value of $186,519.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Jim Brown sold 5,000 shares of the company's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $29.47, for a total transaction of $147,350.00. Following the completion of the transaction, the chief executive officer now owns 15,716 shares of the company's stock, valued at approximately $463,150.52. The trade was a 24.14 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 15,920 shares of company stock valued at $500,285 in the last 90 days. Company insiders own 0.63% of the company's stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.